No matter where you are located, increased travel, climate change, evolving pathogens, emerging pandemics and the need to advance health care practices have put global blood safety at the forefront of industry focus.
With all this change, it’s time to take a proactive approach to protecting patients from the potential dangers of donated blood.
The Mirasol PRT system can help you do it by reducing the pathogen load of a broad range of disease-causing viruses, bacteria and parasites.
The system also inactivates residual white blood cells found in blood components, which may help to reduce transfusion reactions in patients.
The Mirasol PRT system is the only PRT system shown in a human clinical trial to reduce the transfusion-transmitted infection (TTI) of a disease, reducing TTI of malaria by 87 percent.1
We believe better blood safety should provide the right balance of efficacy and ease-of-use while maintaining the quality of blood components for patients who need them. The Mirasol PRT system is a simple system that has the power to deliver better patient care, reducing the risks associated with the lifesaving gift of blood.
The Mirasol PRT system is the only PRT system:
The Mirasol process has fewer steps than other PRT methods and the device can be used to treat platelets, plasma and whole blood. This simplicity helps minimize the impact to operation.8,9,10
The Mirasol PRT system is effective in protecting against a broad spectrum of emerging tested and untested pathogens, including bacteria, parasites, and enveloped and non-enveloped viruses; it also inactivates white blood cells, adding an extra layer of safety for patients. Blood products treated with the Mirasol PRT system maintain efficacy and help save patients’ lives.11,12,13,14,15,16,17,18,19
The Mirasol PRT system treatment can be used as an alternative to some safety procedures without introducing new risks for operators or patients.20,21,22 Treatment with the Mirasol PRT system can help reduce product discard rates for blood centers and reduce the overall cost of transfusion for hospitals.2,3,8,9
The Mirasol PRT system comes from Terumo BCT, a global leader in blood component technologies.
The Mirasol PRT system uses a combination of riboflavin (vitamin B2), a non-toxic, non-mutagenic compound, and a specific spectrum of ultraviolet (UV) light to inactivate viruses, bacteria, parasites and white blood cells that may be present in collected blood products.
The Mirasol PRT system causes irreversible changes to the RNA and DNA of viruses, bacteria, parasites and white blood cells, preventing them from replicating and causing disease.
Trima Accel® Automated Blood Collection System
The Mirasol PRT system is in conformance with the Medical Device Directive.
The Mirasol PRT system is not approved for sale in the U.S. It is available in select markets.
The Mirasol PRT system has received the CE mark for platelet, plasma and whole blood applications.
1Allain JP, et al., "Prevention of Transfusion-Transmitted Malaria by Treatment of Whole Blood With the Mirasol PRT System." Blood 2015; 126 (23): 770.
2Custer B, et al., "The Cost-Effectiveness of Pathogen Reduction Technology as Assessed Using a Multiple Risk Reduction Model." Transfusion 2010; 50 (11): 2461–2473.
3Agapova M, et al., "Introducing Pathogen Reduction Technology in Poland: A Cost Utility Analysis." Transfus Med Hemother 2015; 42 (3): 158–165.
4Goodrich RP and MS Platz, "The Design and Development of Selective, Photoactivated Drugs for Sterilization of Blood Products." Drugs of the Future 1997; 22 (2): 159–171.
5Mundt JM, et al., "Chemical and Biological Mechanisms of Pathogen Reduction Technologies." Photochemistry and Photobiology 2014; 90 (5): 957–964.
6Reddy HL, et al., "Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation." Transfusion Medicine Reviews 2008; 22 (2): 133–153.
7Goodrich RP, et al., Chapter 5: "The Antiviral and Antibacterial Properties of Riboflavin and Light: Applications to Blood Safety and Transfusion Medicine." Flavins: Photochemistry and Photobiology, 2006; Royal Society of Chemistry.
8Jimenez-Marco T, "The Benefits of Working With Mirasol PRT." 4th Mirasol International Users Meeting, Estoril, Portugal, 2014.
9Bautista AM, "Logistics and Economical Aspects of Mirasol Implementation." 5th Mirasol International Users Meeting, Palma de Mallorca, Spain, 2015.
10Jimenez-Marco T, et al., "Role of Riboflavin- and UV Light-Treated Plasma in Prevention of Transfusion-Related Acute Lung Injury." Transfusion Medicine and Hemotherapy 2014; 41 (3): 172–175.
11Marschner S and R Goodrich, "Pathogen Reduction Technology of Platelets, Plasma and Whole Blood Using Riboflavin and UV-Light." Transfusion Medicine and Hemotherapy 2011; 38 (1): 8–18.
12Keil SD, et al., "Inactivation of Viruses in Platelet and Plasma Products Using a Riboflavin-and-UV-based Photochemical Treatment." Transfusion 2015; 55 (7): 1736–1744.
13Keil SD, et al., "Treatment of Platelet Products With Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination." J Vis Exp 2015; (102): 52820.
14Yañez Izquierdo M, et al., "Performance of Buffy Coat Platelets in Plasma Treated With Riboflavin and UV Light: In Vitro and In Vivo Evaluation." Transfusion 2009; 49 (Suppl.): 84A.
15Yañez M, et al., "Clinical Evaluation of Platelets Treated With Riboflavin and UV Light in the Presence of Platelet Additive Solution in Thrombocytopenic Patients." Vox Sanguinis 2011; 101 (Suppl. 1): 148.
16Coene GC, et al., "In Vitro and In Vivo Evaluation of Mirasol Pathogen Reduction Technology Treated Platelets Stored in SSP+." Vox Sanguinis 2011; 101 (Suppl. 1): 188–189.
17Mirasol Clinical Evaluation Study Group and RP Goodrich, "A Randomized Controlled Clinical Trial Evaluating the Performance and Safety of Platelets Treated With Mirasol Pathogen Reduction Technology." Transfusion 2010; 50 (11): 2362–2375.
18Trakhtman P, "Efficacy and Safety of Pathogen-Reduced Platelet Concentrates in Children With Cancer: A Retrospective Cohort Study." Transfusion 2016; 56 (Suppl. 1): S24–S28.
19Kaplan A, et al., "Evaluation of the Post-Transfusion Platelet Increment and Safety of Riboflavin-Based Pathogen Reduction Technology (PRT) Treated Platelet Products Stored in Platelet Additive Solution for 5 Days or Less Versus 6-7 Days." Transfusion and Apheresis Science 2015; 54 (2): 248–252.
20Fast LD, et al., "Inactivation of Human White Blood Cells in Platelet Products After Pathogen Reduction Technology Treatment in Comparison to Gamma-Irradiation." Transfusion 2011; 51 (7): 1397–1404.
21Fast LD, et al., "Treatment of Whole Blood With Riboflavin Plus Ultraviolet Light, an Alternative to Gamma Irradiation in the Prevention of Transfusion-Associated Graft-Versus-Host Disease?" Transfusion 2013; 53 (2): 373–381.
22Goodrich RP, et al., "A Laboratory Comparison of Pathogen Reduction Technology Treatment and Culture of Platelet Products for Addressing Bacterial Contamination Concerns." Transfusion 2009; 49: 1205–1216.
Products available in select markets.